GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (NAS:VCYT) » Definitions » Shiller PE Ratio

Veracyte (Veracyte) Shiller PE Ratio : (As of May. 28, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Veracyte Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Veracyte Shiller PE Ratio Historical Data

The historical data trend for Veracyte's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veracyte Shiller PE Ratio Chart

Veracyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Veracyte Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Veracyte's Shiller PE Ratio

For the Diagnostics & Research subindustry, Veracyte's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veracyte's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Veracyte's Shiller PE Ratio falls into.



Veracyte Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Veracyte's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Veracyte's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.02/131.7762*131.7762
=-0.020

Current CPI (Mar. 2024) = 131.7762.

Veracyte Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.310 100.560 -0.406
201409 -0.370 100.428 -0.485
201412 -0.360 99.070 -0.479
201503 -0.340 99.621 -0.450
201506 -0.350 100.684 -0.458
201509 -0.320 100.392 -0.420
201512 -0.290 99.792 -0.383
201603 -0.360 100.470 -0.472
201606 -0.400 101.688 -0.518
201609 -0.200 101.861 -0.259
201612 -0.140 101.863 -0.181
201703 -0.240 102.862 -0.307
201706 -0.220 103.349 -0.281
201709 -0.210 104.136 -0.266
201712 -0.240 104.011 -0.304
201803 -0.270 105.290 -0.338
201806 -0.180 106.317 -0.223
201809 -0.120 106.507 -0.148
201812 -0.080 105.998 -0.099
201903 -0.050 107.251 -0.061
201906 -0.050 108.070 -0.061
201909 -0.020 108.329 -0.024
201912 -0.150 108.420 -0.182
202003 -0.240 108.902 -0.290
202006 -0.220 108.767 -0.267
202009 -0.080 109.815 -0.096
202012 -0.140 109.897 -0.168
202103 -0.660 111.754 -0.778
202106 -0.130 114.631 -0.149
202109 -0.200 115.734 -0.228
202112 -0.150 117.630 -0.168
202203 -0.200 121.301 -0.217
202206 -0.130 125.017 -0.137
202209 -0.120 125.227 -0.126
202212 -0.050 125.222 -0.053
202303 -0.110 127.348 -0.114
202306 -0.120 128.729 -0.123
202309 -0.410 129.860 -0.416
202312 -0.390 129.419 -0.397
202403 -0.020 131.776 -0.020

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Veracyte  (NAS:VCYT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Veracyte Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Veracyte's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Veracyte (Veracyte) Business Description

Traded in Other Exchanges
Address
6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis products.
Executives
Phillip G. Febbo officer: Chief Scientific & Med Officer C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
John Leite officer: Chief Commercial Officer-CLIA 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Evan/ Fa Jones director C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
John L Bishop director
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Bonnie H Anderson director, officer: President & CEO 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Karin Eastham director C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Giulia C Kennedy officer: Chief Scientific & Med Officer 338 MAIN STREET #26E, SAN FRANCISCO CA 94105
Eliav Barr director C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Jens Holstein director C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Marc Stapley officer: Chief Executive Officer 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Kevin K Gordon director 155 S LIMERICK RD, LIMERICK PA 19468
Jonathan Wygant officer: VP, Chief Accounting Officer 3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Annie Mcguire officer: SVP, General Counsel C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Rebecca Chambers officer: Chief Financial Officer 3052 ORCHARD DR., SAN JOSE CA 95134

Veracyte (Veracyte) Headlines

From GuruFocus

Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023

By Business Wire Business Wire 06-12-2023